Evidence map›Paper›PMID 34558178›Full record

ArticleJournal of cellular and molecular medicine2021

Five-in-One: Simultaneous isolation of multiple major liver cell types from livers of normal and NASH mice.

Ye Zhou, Funmilola Adewale, Sun Kim, Qi Su, David Glass, Mark W Sleeman, Andrew J Murphy, Xiping Cheng

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Hepatic targeting of the centrally active cannabinoid 1 receptor (CBJournal of controlled release : official journal of the Controlled Release Society · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ye ZhouRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.ORCID 0000-0003-3861-3120
Funmilola AdewaleRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Sun KimRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Qi SuRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
David GlassRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Mark W SleemanRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Andrew J MurphyRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Xiping ChengRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Regeneron (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NASH is a chronic liver disease that affects 3%-6% of individuals and requires urgent therapeutic developments. Isolating the key cell types in the liver is a necessary step towards understanding their function and roles in disease pathogenesis. However, traditional isolation methods through gradient centrifugation can only collect one or a few cell types simultaneously and pose technical difficulties when applied to NASH livers. Taking advantage of identified cell surface markers from liver single-cell RNAseq, here we established the combination of gradient centrifugation and antibody-based cell sorting techniques to isolate five key liver cell types (hepatocytes, endothelial cells, stellate cells, macrophages and other immune cells) from a single mouse liver. This method yielded high purity of each cell type from healthy and NASH livers. Our five-in-one protocol simultaneously isolates key liver cell types with high purity under normal and NASH conditions, enabling for systematic and accurate exploratory experiments such as RNA sequencing.

Indexed as

Cell SeparationAnimalsBiomarkersDisease Models, AnimalEndothelial CellsFluorescent Antibody TechniqueHepatocytesImmunophenotypingLiverMacrophagesMaleMiceNon-alcoholic Fatty Liver DiseaseBiomarkerscell isolationfluorescence-activated cell sortinglivernon-alcoholic steatohepatitis

Identifiers

PMID34558178
PMCPMC8505823
OpenAlexW3200842185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.